Dr Reddy's launches anti-nausea injection for cancer patients in US

Drug is a therapeutic equivalent of USFDA-approved Aloxi injection, whose sales in 12 months to Jan 2018 were $446 mn

Dr Reddy's Laboratories Limited announced on Monday that it has launched Palonosetron Hydrochloride Injection, 0.25 mg/ml, a therapeutic equivalent of Aloxi Injection approved by the US Food and Drug Administration (USFDA).

The drug is used to treat chemotherapy-induced nausea and vomiting sensation. 

The Aloxi brand and generic had US sales of approximately $446 million for twelve months ending in January 2018, according to IMS Health.

Dr Reddy's injection is available in a single-dose vial packed in a carton containing one vial, according to the company. 

The shares of the company were trading at Rs 2,060, down 0.67 per cent, at around 11:30 a.m. on the Bombay Stock Exchange on Monday.